Reactivation of hepatitis B virus with rituximab

Bibliography

• GALBRAITH RM, EDDLESTON AL, WILLIAMS R, ZUCKERMAN AJ, BAGSHAWE KD: Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet (1975) 2:538–530.
   PubMedGoogle Scholar
• HOONFNAGLE JH, DUSHEIKO GM, SCHAFER DF et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Intern. Med. (1982) 96:447–449.
   PubMed Web of Science ®Google Scholar
• THUNG SN, GERBER MA, KLION F, GILBERT H: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch. Intern. Med. (1985) 145:1313–1314.
   PubMed Web of Science ®Google Scholar
• LAU JY, LAI CL, LIN HJ et al: Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Quart. J. Med. (1989) 73:911–917.
   PubMedGoogle Scholar
• BIRD GL, SMITH H, PORTMANN B, ALEXANDER GJ, WILLIAMS R: Acute liver decompensation of withdrawal of cytotoxic and immunosuppressive therapy in hepatitis B carriers. Quart. J. Med. (1989) 73:895–902.
   PubMedGoogle Scholar
• LIANG RHS, LOK ASF, LAI CL, CHAN TK, TODD 0, CHIU EKW: Hepatitis B infection in patients with lymphomas. Hernatol Oncol (1990) 8:261–270.
   PubMed Web of Science ®Google Scholar
• LOK ASF, LAI CL, WU PC: Hepatitis Bvirus infection in Chinese families in Hong Kong. Am. J. Epiderniol (1987) 126:492–499.
   PubMed Web of Science ®Google Scholar
• LOK ASF, LIANG RHS, CHIU EKW, WONG KL, CHAN TK, TOOD D: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology (1991) 100:182–188.
   PubMed Web of Science ®Google Scholar
• PINTO PC, HUE, BERNSTEIN-SINGER M, PINTER-BROWN L, GOVINDARAJAN S: Acute hepatic injury after withdrawal of immunosuppressive chemotherapy in patients with hepatitis B. Cancer (1990) 65:878–884.
   PubMed Web of Science ®Google Scholar
• SOH LT, ANG PT, SNG I, CHUA EJ, ONG YW: Fulminant hepatic failure in non-Hodgkin's lymphoma patients treated with chemotherapy. Eur. J. Cancer (1992) 28A:1338–1339.
   PubMed Web of Science ®Google Scholar
• NAKAMURA Y, MOTOKURA T, FUJITA A, YAMASHITA T, OGATA E: Sever hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: survey in Japan, 1987-1991.Cancer (1996) 78:2210–2215.
   PubMed Web of Science ®Google Scholar
• KUMAGAI K, TAKAGI T, NAKAMURA S et al: Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann. Oncol (1997) 8:107–109.
   PubMed Web of Science ®Google Scholar
• YEO W, CHAN PKS, ZHONG S et al:Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J. Med. Viral. (2000) 62:299–307.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, LILES TM, CZERWINSKI DK et al.: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 84:2457–2466.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, BODKIN D et al: IDEC-C2B8: Results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. I Clin. Oncol (1997) 15:3266–3274.
   PubMed Web of Science ®Google Scholar
• MACLAUGHLINP, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Oncol (1998)16:2825–2833.
   Google Scholar
• TOBINAI K, KOBAYASI Y, NARABAYASHI M et al., and Members of the IDCE-C2B8 study groupe. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in a relapsed B-cell lymphoma. Ann. Oncol (1998) 9:527–534.
   Google Scholar
• IGARASHI T, OHTSU T, FUJII H et al.,and Members of the IDEC-C2B8 Study Group. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. bit. J. Hernatol (2001) 73:213–221.
   Google Scholar
• COIFFER B, HAIOUN N, ENGERT KA et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92: 1927-1932.
   Google Scholar
• FORAN JM, ROHATINER AZS, CUNNINGHAM D et al: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma, immunocytome, and small B-cell lymphocytic lymphoma. I Clin. Oncol (2000) 18:317–324.
   PubMed Web of Science ®Google Scholar
• DAVIS TA, WHITE CA, GRILLO-LOPEZ AJ et al: Single-agent monoclonal antibody efficacy in bulkey non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. Clin. Oncol (1999) 17:1851–1857.
   Web of Science ®Google Scholar
• GHIELMINI M, HSH SCHMITZ SF, BURKI K et al.: The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann. Oncol (2000) 11:S123–S126.
   Google Scholar
• KUNKEL L, WONG A, MANEATIS T et al.: Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: A benefit-risk update. Semin. Oncol (2000) 27:53–61.
   PubMed Web of Science ®Google Scholar
• TOBINAI K: Monoclonal antibody therapyfor B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int. J. Hematol (2002) 76:411–419.
   PubMed Web of Science ®Google Scholar
• IGARASHI T, KOBAYASHI Y, OGURA M et al: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese Phase II study. Ann. Oncol (2002) 13:928–943.
   PubMed Web of Science ®Google Scholar
• TOBINAI K, IGARASHI T, KOBAYASHI Y et al: Japanese multicenter Phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma. Ann. Oncol (2004) 15:821–830.
   PubMed Web of Science ®Google Scholar
• ROTHE A, SCHULZ H, ELTER T, ENGERT A, REISER M: Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma. Haematologica (2004) 89:875–876.
   PubMedGoogle Scholar
• SEYMOUR JF: New treatment approachesto indolent non-Hodgkin's lymphoma. Semin. Oncol (2004) 31:27–32.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, WEAVER R, ALKUZWENY B, BERLFEIN J, GRILLO-LOPEZ AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Clin. Oncol (2004) 22:4711–4716.
   Web of Science ®Google Scholar
• BERMUDEZ A, MARCO F, CONDE E, MAZO E, RECIO M, ZUBIZARRETA A: Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica (2000) 85:894–895.
   PubMed Web of Science ®Google Scholar
• SHARMA VR, FLEMING DR, SLONE S: Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood (2000) 96:1184–1186.
   PubMed Web of Science ®Google Scholar
• SUZAN F, AMMOR M, RIBRAG V: Fatal reactivation of cytomegalovirus infection after use of rituximab for a post transplantation lymphoproliferative disorder. N Engl. J. Med. (2001) 345:1000.
   PubMed Web of Science ®Google Scholar
• GOLDBERG SL, PECORA AL, ALTER RS et al.: Unusual wiral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood (2002) 99:1486–1488.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al: Treatment of patients with low grade B-cell lymphoma with the combination of chemeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol (1999) 17:268–276
   PubMed Web of Science ®Google Scholar
• HERNANDEZ JA, DILOY R, SALAT D, DEL RIO N, MARTINEZ X, CASTELLVI JM: Fluminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. Haematologica (2003) 88:ECR22.
   Google Scholar
• SKRABS C, MULLER C, AGIS H, MANNHALTER C, JAGER U: Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia (2002) 16:1884–1886.
   PubMed Web of Science ®Google Scholar
• WESTHOFF TH, JOCHIMSEN F, SCHMITTEL A et al.: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood (2003) 102:1930.
   PubMed Web of Science ®Google Scholar
• NG HJ, LIM LC: Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report. Ann. Hematol (2001) 80:549–552.
   PubMed Web of Science ®Google Scholar
• JAGER G, NEUMEISTER P, BREZINSCHEK R et al.: Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a Phase II study. Eur.j Haematol (2002) 69:21–26.
   PubMed Web of Science ®Google Scholar
• DERVITE I, HOBER D, MOREL P: Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Med. (2001) 344:68–69.
   PubMed Web of Science ®Google Scholar
• ROSSINI F, CAPALBO S, FUMAGALLI M et al: 'Standard dose' rituximab in refractory chronic lymphocytic leukemia. Hematol J. (2002) 3\(Suppl. 1) [0827].
   Google Scholar
• DOMINGO-DOMENECH E, GONZALEZ-BARCA E, ESTANY C, SUREDA A, BESALDUCH J, DE SEVILLA AF: Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica (2002) 87:1229–1230.
   PubMed Web of Science ®Google Scholar
• TSUTSUMI Y, KAWAMURA T, SAITOH S et al.: Hepatitis B virus reactivation in a case of Non-Hodgkin's lymphoma treated with chemotherapy and rituximab (necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy). Leuk. Lymphoma (2004) 45:627–629.
   PubMed Web of Science ®Google Scholar
• TSUTSUMI Y, TANAKA J, KAWAMURA T et al: Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann. Haematol (2004) 83:58–60.
   PubMed Web of Science ®Google Scholar
• •This report shows the changes of the anti-HBs after administration of rituximab.
   Google Scholar
• MIMIDIS K, TSATALAS C, MARGARITIS D et al: Efficacy of lamivdine in patients with hamatologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol (2002) 107:49–51.
   PubMed Web of Science ®Google Scholar
• HAMAKI T, KAMI M, KUSUMI E et al:Prophylaxis of hapatitis B reactivation using lamivdine in a patient receiving rituximab. Am. J. Hematol (2001) 68:292–294.
   PubMed Web of Science ®Google Scholar
• KAMI M, HAMAKI T, MURASHIGE N et al.: Safty of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J. (2003) 4:159–162.
   PubMedGoogle Scholar
• •This report shows the efficacy of the lamiyudine prophylaxis against HBV-reactivation.
   Google Scholar
• REFF ME, CARNER K, CHAMBERS KSet al.: Depletion of B-cells in vivo bya chimeric mouse human monoclonal antibody to CD20.Blood (1994) 83:435–445.
   Google Scholar
• UPRICHARD SL, WIELAND SF, ALTHAGE A, CHISARI FV: Transcriptional and posttranscriptional control of hepatitis B virus gene expression. Proc. Natl. Acad. ScL USA (2003) 100:1310–1315.
   PubMed Web of Science ®Google Scholar
• THIMME R, WIELAND S, STEIGER C et al: CD8+ T-cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. .1 Viol. (2003) 77:68–76.
   Google Scholar
• SHI TD, WU YZ, JIA ZC, ZOU LY, ZHOU W: Therapeutic polypeptides based on HBV core 18-27 epitope can induce CD8+ CTL-mediated cytotoxicity in HLA-A2+ human PBMCs. World J. Gastroenterol. (2004) 10:1902–1906.
   PubMed Web of Science ®Google Scholar
• COIFFER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl. I Med. (2002) 346:235–242.
   PubMed Web of Science ®Google Scholar
• YOSHIBA M, SEKIYAMA K, INOUE K, FUJITA R: Interferon and cyclosporinA in the treatment of fulminant viral hepatitis. Gastroenterol. (1995) 30:67–73.
   Web of Science ®Google Scholar
• VENTO S, CAINELLI F, LONGHI MS: Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol. (2002) 3:333–340.
   PubMed Web of Science ®Google Scholar
• •This report shows the rate of the HBV-reactivation in relation to antigen and antibody of HBV.
   Google Scholar
• LAU GKK, YIU HHY, FONG DYT et al.: Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology (2003) 125:1742–1749.
   PubMed Web of Science ®Google Scholar
• ••This report shows that patients withlamivudine treatment according to the monitoring of HBV DNA more often developed hepatitis of HBV-reactivation than patients with the prophylaxis treatment of lamivudine.
   Google Scholar
• AL-TAIE OH, MORK H, GASSEL AM, WILHELM M, WEISSBRICH B, SCHEURLEN M: Prevention of hepatitis B flare-up during chemotherapy using lamivdine: case report and review of the literature. Ann. Hematol. (1999) 78:247–249.
   PubMed Web of Science ®Google Scholar
• SILVESTRI F, ERMACORA A, SPEROTTO A et al.: Lamivdine allows completion of chemotherapy in lymphoma patients with hapatitis B reactivation. Br. J. Haematol. (2000) 108:394–396.
   PubMed Web of Science ®Google Scholar
• SHIBOLET 0, GILLIS S, HUBERT A,SHOUVAL D, SAFADI R: Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood (2002) 100:391–396.
   PubMed Web of Science ®Google Scholar
• ESTEVE M, SARO C, GONZALEZ-HUIX F, SUAREZ F, FORNE M, VIVER JM: Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut (2004) 53:1363–1365.
   PubMed Web of Science ®Google Scholar
• PELIZZARI AM, MOTTA M, CARIANI E, TURCONI P, BORLENGHI E, ROSSI G: Frequency of hepatitis B virus mutant in asymptomatic hepatitis virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol. 1 (2004) 5:325–328.
   Web of Science ®Google Scholar
• •This report shows several durations of the administration of lamivudine from the start of chemotherapy.
   Google Scholar
• BRUNETTO MR, STEMLER M, SHODEL F et al.: Identification of HBV variants which cannot produce pre-core derived HbeAg and may be responsible for severe hepatitis. Ital. J. Gastroenterol. (1989) 21:151–154.
   Google Scholar
• CARMA WE JACYNA MR, HADZIYANNIS S et al: Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet (1989) 2:588-591Brunetto MR, Giarin MM, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl. Acad. Li. USA (1991) 88:4186–4190.
   Google Scholar
• BRUNETTO MR, GIARIN MM, OLIVERI F et al: Wild-type and e antigen minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl. Acad. Li. USA (1991) 88:4186–4190.
   PubMed Web of Science ®Google Scholar
• MURASAWA H, UMEMOTO S, HIJIKATA M et al: Latent hepatitis B infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology (2000) 31:488–495.
   PubMed Web of Science ®Google Scholar
• YEO W, ZEE B, ZHONG S et al.: Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivatio in cancer patients undergoin cytotoxic chemotherapy. BE J. Cancer (2004) 90:1306–1311.
   Web of Science ®Google Scholar
• LOK AS, HEATHCOTE EJ, HOOFNAGEL JH: Management of Hepatitis B 2000-Summary of a workshop. Gastroenterology (2001) 120: 1828-1853.
   Google Scholar
• LOK ASF, MCMAHON BJ: Chronic hepatitis B: update of recommendations. Hepatology (2004) 39:857–861.
   PubMed Web of Science ®Google Scholar
• LOK ASF, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34:1225–1241.
   PubMed Web of Science ®Google Scholar
• ••These two reports [68,69] show thecurrent treatment of hepatitis B.
   Google Scholar
• DAI MS, CHAO TY, KAO WY, SHYU RY, LIU TM: Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann. Hematol. (2004) 83:769–774.
   PubMed Web of Science ®Google Scholar
• ••This report shows delayedHBV-reactivation was observed after discontinued lamivudine prophylaxis treatment.
   Google Scholar
• PICARDI M, PANE F, QUINTARELLI C et al.: Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica (2003) 88:1296–1303.
   PubMed Web of Science ®Google Scholar
• PETERS MG, HANN HW, MARTIN P et al: Adeforvir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 126:91–101.
   PubMed Web of Science ®Google Scholar
• •This report shows adeforvir treatment in patients with lamivudine-resistant chronic hepatitis B.
   Google Scholar
• PEREZ-ROLDAN F, GONZALEZ-CARRO P, VILLAFANEZ-GARCIA MC: Adeforvir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N. Engl. J. Med. (2004) 352:310–311.
   Google Scholar
• TILLMANN HL, WEDEMEYER H, MANNS MP: Treatment of hepatitis B in special patient groups: hemodialysis heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. .1 Hepatol. (2003) 39:S206–S211.
   PubMed Web of Science ®Google Scholar